Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elena R. Vasilescu is active.

Publication


Featured researches published by Elena R. Vasilescu.


International Reviews of Immunology | 2010

Membrane and Soluble ILT3 Are Critical to the Generation of T Suppressor Cells and Induction of Immunological Tolerance

George Vlad; Chih-Chao Chang; Adriana I. Colovai; Elena R. Vasilescu; Raffaello Cortesini; Nicole Suciu-Foca

The tolerogenic phenotype of human dendritic cells is characterized by high cell surface expression of the inhibitory receptor ILT3. ILT3 signals both intracellularly inhibiting tyrosine phosphorylation, NF-κB and MAPK p38 activity, transcription of certain co-stimulatory molecules, secretion of cytokines and chemokines, and extracellularly into the T cells with which the dendritic cells interact. Both ILT3high tolerogenic dendritic cells and soluble ILT3 induce CD4 Th anergy and differentiation of antigen specific CD8 T suppressor cells. Recombinant ILT3-Fc protein has important immunotherapeutic potential acting directly on activated T cells and promoting the induction of immunological tolerance.


Pediatric Transplantation | 2011

HLA antibodies in pediatric heart transplantation

Eric K. Ho; Elena R. Vasilescu; George Vlad; Charles C. Marboe; Linda J. Addonizio; Nicole Suciu-Foca

Ho EK, Vasilescu ER, Vlad G, Marboe CC, Addonizio LJ, Suciu‐Foca N. HLA antibodies in pediatric heart transplantation.
Pediatr Transplantation 2011: 15: 458–464.


Journal of Heart and Lung Transplantation | 2017

Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation

Kevin J. Clerkin; Maryjane Farr; S. Restaino; Emmanuel Zorn; F. Latif; Elena R. Vasilescu; Charles C. Marboe; P.C. Colombo; Donna Mancini

BACKGROUND Donor-specific anti-HLA antibodies (DSA) are common after heart transplantation and are associated with rejection, cardiac allograft vasculopathy, and mortality. A noninvasive diagnostic test for pathologic antibody-mediated rejection (pAMR) does not exist. METHODS From January 1, 2010, through August 31, 2013, 221 consecutive adult patients underwent heart transplantation and were followed through October 1, 2015. The primary objective was to determine whether the presence of DSA could detect AMR at the time of pathologic diagnosis. Secondary analyses included association of DSA (stratified by major histocompatibility complex class and de novo status) during AMR with new graft dysfunction, graft loss (mortality or retransplantation), and development of cardiac allograft vasculopathy. RESULTS During the study period, 69 patients (31.2%) had DSA (24% had de novo DSA), and there were 74 episodes of pAMR in 38 patients. Sensitivity of DSA at any mean fluorescence intensity to detect concurrent pAMR was only 54.3%. The presence of any DSA during pAMR increased the odds of graft dysfunction (odds ratio = 5.37; 95% confidence interval [CI], 1.34-21.47; p = 0.018), adjusting for age, sex, and timing of AMR. Circulating class II DSA after transplantation increased risk of future pAMR (hazard ratio = 2.97; 95% CI, 1.31-6.73; p = 0.009). Patients who developed de novo class II DSA had 151% increased risk of graft loss (contingent on 30-day survival) compared with patients who did not have DSA (95% CI, 1.11-5.69; p = 0.027). CONCLUSIONS DSA were inadequate to diagnose pAMR. Class II DSA provided prognostic information regarding future pAMR, graft dysfunction with pAMR, and graft loss.


Journal of Heart and Lung Transplantation | 2016

The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection

Kevin J. Clerkin; S. Restaino; Emmanuel Zorn; Elena R. Vasilescu; Charles C. Marboe; Donna Mancini

BACKGROUND Antibody-mediated rejection (AMR) has been associated with increased death and cardiac allograft vasculopathy (CAV). Early studies suggested that late AMR was rarely associated with graft dysfunction, whereas recent reports have demonstrated an association with increased mortality. We investigated the timing of AMR and its association with graft dysfunction, death, and CAV. METHODS This retrospective cohort study identified all adult orthotopic heart transplant (OHT) recipients (N = 689) at Columbia University Medical Center from 2004 to 2013. There were 68 primary cases of AMR, which were stratified by early (< 1 year post-OHT) or late (> 1 year post-OHT) AMR. Kaplan-Meier survival analysis and modeling was performed with multivariable logistic regression and Cox proportional hazards regression. RESULTS From January 1, 2004, through October 1, 2015, early AMR (median 23 days post-OHT) occurred in 43 patients and late AMR (median 1,084 days post-OHT) occurred in 25. Graft dysfunction was less common with early compared with late AMR (25.6% vs 56%, p = 0.01). Patients with late AMR had decreased post-AMR survival compared with early AMR (1 year: 80% vs 93%, 5 years: 51% vs 73%, p < 0.05). When stratified by graft dysfunction, only those with late AMR and graft dysfunction had worse survival (30 days: 79%, 1 year: 64%, 5 years: 36%; p < 0.006). The association remained irrespective of age, sex, donor-specific antibodies, left ventricular assist device use, reason for OHT, and recovery of graft function. Similarly, those with late AMR and graft dysfunction had accelerated development of de novo CAV (50% at 1 year; hazard ratio, 5.42; p = 0.009), whereas all other groups were all similar to the general transplant population. CONCLUSIONS Late AMR is frequently associated with graft dysfunction. When graft dysfunction is present in late AMR, there is an early and sustained increased risk of death and rapid development of de novo CAV despite aggressive treatment.


Transplantation | 2009

Comparative Outcome Analysis of ABO-Incompatible and Positive Crossmatch Renal Transplantation: A Single-Center Experience

Anand Padmanabhan; Lloyd E. Ratner; Jeffrey S. Jhang; Jimmy K. Duong; Glen S. Markowitz; Elena R. Vasilescu; Russell J. Crew; Joseph E. Schwartz

Background. ABO-incompatible (ABOi) and positive crossmatch (XM) renal transplants pose special immunologic challenges. It is important to compare outcomes, study resource utilization, and attempt to risk stratify patients in these higher risk transplant settings. Methods. We compared apheresis utilization and transplant outcomes in ABOi, XM, and combined ABOi-XM renal transplants. We also analyzed multiple parameters, including patient and laboratory variables, to identify predictors of transplant outcome. Results. Incidences of early (≤30 days posttransplant) antibody-mediated rejection (AMR) and acute cellular rejection (ACR) were similar among the three incompatible groups whereas they differed in allograft rejection for late (>30 days posttransplant) AMR and ACR. Notably, there were no episodes of late AMR among ABOi patients. Patients treated with more than four pretransplant plasmapheresis/intravenous immunoglobulin (PP/IVIg) had a greater likelihood of experiencing early AMR. The median number of posttransplant PP/IVIg treatments was greater than twofold higher in ABOi-XM and XM patients compared to ABOi patients. Patients who required more than five posttransplant PP/IVIg procedures and those with one or more prior renal transplants had higher incidences of late ACR. Conclusions. Our analysis aids in defining apheresis resource utilization and helps in risk stratification of incompatible renal transplantation. It also aids in predicting allograft rejection and provides an opportunity for preemptive monitoring and treatment.


Human Immunology | 2009

Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc.

George Vlad; Michael B. Stokes; Zhuoru Liu; Chih Chao Chang; Hugo Sondermeijer; Elena R. Vasilescu; Adriana I. Colovai; Pasquale Berloco; Lloyd E. Ratner; Raffaello Cortesini; Nicole Suciu-Foca

Allogeneic hematopoietic cell transplantation represents an important therapy for certain malignant and nonmalignant diseases. However, graft-versus-host disease (GVHD) is a major cause of mortality and morbidity. The search for agents that can efficiently suppress GVHD has been going on for more than half a century. GVHD is particularly strong in xenogeneic donor-recipient combinations, given the unlimited number of potentially immunogenic antigens donor lymphocytes encounter in the host. Using a hu-nonobese diabetic/severe combined immunodeficiency (hu-NOD/SCID) gamma-null model of xenogeneic GVHD, we have demonstrated that treatment with recombinant immunoglobulin-like transcript 3-Fc protein induces the differentiation of CD8(+) T suppressor cells and blocks the cellular and humoral arm of the GVH reaction.


Transplantation direct | 2017

Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays

Kevin J. Clerkin; Sarah B. See; Maryjane Farr; S. Restaino; Geo Serban; Farhana Latif; Lingzhi Li; P.C. Colombo; George Vlad; Bryan Ray; Elena R. Vasilescu; Emmanuel Zorn

Background Allospecific anti-HLA antibodies (Abs) are associated with rejection of solid organ grafts. The 2 main kits to detect anti-HLA Ab in patient serum are commercialized by Immucor and One Lambda/ThermoFisher. We sought to compare the performance of both platforms. Methods Background-adjusted mean fluorescence intensity (MFI) values were used from both platforms to compare sera collected from 125 pretransplant and posttransplant heart and lung transplant recipients. Results Most HLA class I (94.5%) and HLA class II (89%) Abs with moderate to high MFI titer (≥4000) were detected by both assays. A modest correlation was observed between MFI values obtained from the 2 assays for both class I (r = 0.3, r2 = 0.09, P < 0.0001) and class II Ab (r = 0.707, r2 = 0.5, P < 0.0001). Both assays detected anti–class I and II Ab that the other did not; however, no specific HLA allele was detected preferentially by either of the 2 assays. For a limited number of discrepant sera, dilution resulted in comparable reactivity profiles between the 2 platforms. Conclusions Immucor and One Lambda/ThermoFisher assays have a similar, albeit nonidentical, ability to detect anti-HLA Ab. Although the correlation between the assays was present, significant variances exist, some of which can be explained by a dilution-sensitive “prozone” effect.


Human Immunology | 2014

Detection of donor-specific-antibodies by solid phase assay and its relevance to complement-dependent-lymphocytotoxicity cross-matching in kidney transplantation

Eric K. Ho; Elena R. Vasilescu; George Vlad; Raphael Clynes; Lloyd E. Ratner; Nicole Suciu-Foca

Presensitization against a broad array of HLA is associated with prolonged waiting times and inferior kidney allogaft survival. Although the use of solid phase assay (SPA) for the detection and characterization of anti-HLA antibodies provides greater sensitivity than complement-dependent lymphocytotoxicity (CDC) assay, it often detects donor specific antibodies (DSA) which turn out to be clinically irrelevant. Our data reinforce the concept that these two types of assays should be used in parallel for pre-and post-transplantation monitoring of anti-HLA antibodies in recipients of solid organ allografts.


Transplantation | 2010

NEW ONSET GRAFT DYSFUNCTION AFTER HEART TRANSPLANTATION - INCIDENCE AND MECHANISM-RELATED IN-HOSPITAL OUTCOMES: 3115

Khurram Shahzad; Q. A. Aziz; Martin Cadeiras; J. Leva; Eric K. Ho; G. Vlad; Elena R. Vasilescu; F. Latif; A. Sinha; Elizabeth Burke; Linda J. Addonizio; Charles C. Marboe; Nicole Suciu-Foca; Mario C. Deng

Introduction: Graft dysfunction (GD) with or without histological signs of rejection after heart transplantation (HTx) is a major cause of morbidity and mortality. The impact of different pathophysiological mechanisms on outcome is unknown. In this large single-center study we wanted to assess the incidence and the impact of different mechanisms on outcomes of graft dysfunction (GD). Methods: We analyzed consecutive HTx patients at Columbia University Medical Center between January 1994 and March 2008 and identified all patients hospitalized with GD (heart failure with LEF≤30%). Histopathological data was collected at the time of admission to understand the mechanisms of GD. Patients were divided into GDacute cellular rejection (Group-GD-ACR) with ISHLT grade ≥1R/1B, GD-antibody mediated rejection (Group-GD-AMR) with positive C4d staining, GD-cardiac allograft vasculopathy (Group-GD-CAV) with ≥25% blockage in one of the three main coronary arteries (LAD, LCX, and RCA), and GD-unexplained (Group-GD-U). We compared the in-hospital mortality outcomes across these groups using Chi-square test. Results: Out of 126 patients (12%) identified with GD, complete histology data was available for 100 patients. There were 27 patients, 15 patients, 24 patients, and 34 patients identified in Group-GD-U, Group-GD-AMR, Group-GD-CAV, and Group-GD-ACR respectively. The in-hospital mortality rate was significantly higher in Group-GD-U as compared to all other groups (48%, p=0.0008) [Figure1].


Human Immunology | 2009

Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival

George Vlad; Eric K. Ho; Elena R. Vasilescu; Adriana I. Colovai; Michael B. Stokes; Glen S. Markowitz; David J. Cohen; Lloyd E. Ratner; Nicole Suciu-Foca

Collaboration


Dive into the Elena R. Vasilescu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Charles C. Marboe

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Donna Mancini

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Lloyd E. Ratner

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Glen S. Markowitz

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David J. Cohen

Columbia University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge